Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
Want to see IMDX full AI Analyst Report?
IMDX Stock Chart & Stats
$3.17
--
Market closed
$3.17
--
Day’s Range― - ―
52-Week Range$2.33 - $8.51
Previous CloseN/A
VolumeN/A
Average Volume (3M)42.75K
Market Cap
$200.52M
Enterprise Value$141.55M
Total Cash (Recent Filing)$28.20M
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Aug 06, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding32,290,170
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue72.63
Enterprise Value/Gross Profit373.00
Enterprise Value/Ebitda-2.75
Forecast
1Y Price Target
$10.50Price Target Upside231.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$2.59M
Bulls Say, Bears Say
Bulls Say
FDA Submission ProgressA completed FDA submission and reported productive engagement materially de-risks U.S. regulatory pathway. Sustained FDA interactions increase the probability of market authorization and first U.S. orders, creating a durable route to recurring kit and service revenues tied to clinical adoption.
Medicare Reimbursement AnchorA clear Medicare reimbursement amount provides an enduring pricing and payment anchor that strengthens unit economics. Reliable reimbursement supports hospital adoption, revenue predictability per test, and makes payer negotiations and commercial scaling more feasible over the medium term.
Clinical Registry MomentumGrowing GALACTIC registry participation builds clinical evidence and institutional trust, a durable driver of adoption for diagnostics. Broader center enrollment accelerates head-to-head data generation, referral pathways, and sustainable sample volumes that support long-term commercial traction.
Bears Say
Sharp Revenue DeclineA more-than-50% decline in trailing revenue signals weak commercial traction and a very small revenue base versus fixed costs. This structural shortfall lengthens the time to scale, amplifies sensitivity to single milestones, and increases reliance on successful regulatory and commercialization execution to restore sustainable top-line growth.
Persistent Heavy Cash BurnSustained negative operating and free cash flow requires ongoing external financing. Elevated burn depletes runway, raises dilution and refinancing risk, and can force trade-offs between R&D and commercial investment, undermining the company’s ability to execute a steady commercialization plan without repeated capital raises.
Negative Stockholders' EquityNegative shareholders' equity reflects accumulated losses and weak balance sheet cushion. This structural weakness limits borrowing capacity, heightens refinancing and dilution risk, and reduces financial flexibility to support instrument placements, manufacturing scale-up, and multi-market commercialization.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $2.33 and its highest was $8.51 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $200.52M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Aug 06, 2026 which is in 66 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on May 13, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.262 by $0.142.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,290,170 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.262. Following the earnings report the stock price went up 25.882%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (231.23% Upside)
$10.50 (231.23% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.71%
12-Months-Change
Fundamentals
Return on Equity
380.80%
Trailing 12-Months
Asset Growth
-33.02%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
IMDX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear operational and regulatory progress (FDA submission engagement, ISO certification, registry momentum, pricing validation, TAM affirmation, emerging head-to-head data and organ expansion), balanced against near-term financial pressures (Q2 cash burn >$9M, very low near-term revenue ~$0.25M), commercialization constraints (instrument placement), and timing uncertainty in Europe and FDA review details. Management provided concrete targets for margins, cost structure, and runway management and expects cash burn to decline in the back half of the year. Overall, the call signals meaningful de-risking and commercialization preparation while acknowledging near-term financial drag.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$10.50
▲(231.23% Upside)
Technical Analysis
Ownership Overview
80.04% Insiders
1.90% Mutual Funds
4.15% Other Institutional Investors
12.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---